Based on this finding, Eshhar and colleagues developed the first generation of a CAR construct which carried the antigen-binding domain of a Neu/Her2 antibody as an extracellular domain and an intracellular CD3ζ signaling domain to promote the MHC-independent recognition pathway for T cells and an effective elimination of adenocarcinoma cells upon interaction with the target antigen [88]. This evidence concerns the gene ERBB2 and adenocarcinoma.